🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "major milestone" in the effort against drug-resistant strains of the infection, according to researchers.

A Worldwide Challenge

Gonorrhoea infections are escalating worldwide, with estimates suggesting in excess of 82 million new cases each year. Notably increased rates are observed in the African continent and countries within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. Across England, cases have reached a record high, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune step in the context of growing infection rates, increasing antimicrobial resistance and the highly restricted available drugs presently on offer.”

Health officials are particularly alarmed about the surge in antibiotic-resistant strains. The World Health Organization has classified it as a "critical concern". Recent surveillance revealed that resistance to key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Treatment Options Receive Clearance

Zoliflodacin, also known as a brand name, was approved by the American regulatory agency in December for treating gonorrhoea. This STI can lead to serious health problems, including infertility. Experts believe that focused deployment of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, also received approval in close succession. This treatment, which is employed against urinary tract infections, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Development Model

This new treatment was the result of a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to develop it.

“This approval represents a huge turning point in the management of superbug gonorrhoea, which previously has been staying ahead of antibiotic development.”

Research Study Results and Worldwide Availability

As per results published in a major medical journal, zoliflodacin successfully treated more than 90% of cases of the STI. This places it at an comparable level with the typical regimen, which combines a dual-drug approach. The trial enrolled nearly 1,000 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, the non-profit has the rights to license and sell the drug in a wide range of regions with limited resources.

Clinicians on the front lines have voiced positive views. Having a easy-to-administer therapy of this kind is hailed as a "revolutionary step" for gonorrhoea control. This is deemed vital to alleviate the strain of the infection for patients and to stop the proliferation of untreatable gonorrhoea worldwide.